APOE genotype and MRI markers of cerebrovascular disease
Systematic review and meta-analysis
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: We aimed to examine the association of APOE ε genotype with MRI markers of cerebrovascular disease (CVD): white matter hyperintensities, brain infarcts, and cerebral microbleeds.
Methods: We performed a systematic review and meta-analysis of 42 cross-sectional or longitudinal studies identified in PubMed from 1966 to June 2012 (n = 29,965). This included unpublished data from 3 population-based studies: 3C-Dijon, Framingham Heart Study, and Sydney Memory and Ageing Study. When necessary, authors were contacted to provide effect estimates for the meta-analysis.
Results: APOE ε4 carrier status and APOE ε44 genotype were associated with increasing white matter hyperintensity burden (sample size–weighted z score meta-analysis [meta]-p = 0.0034 and 0.0030) and presence of cerebral microbleeds (meta odds ratio [OR] = 1.24, 95% confidence interval [CI] [1.07, 1.43], p = 0.004, and 1.87 [1.26, 2.78], p = 0.002), especially lobar. APOE ε2 carrier status was associated with increasing white matter hyperintensity load (z score meta-p = 0.00053) and risk of brain infarct (meta OR = 1.41[1.09, 1.81], p = 0.008).
Conclusions: APOE ε4 and APOE ε2 were associated with increasing burden in MRI markers for both hemorrhagic and ischemic CVD. While the association of APOE ε4 with an increased burden of CVD could be partly contributing to the relationship between APOE ε4 and AD, APOE ε2 was associated with MRI markers of CVD in the opposite direction compared to AD.
GLOSSARY
- Aβ=
- amyloid β;
- AD=
- Alzheimer disease;
- BI=
- brain infarcts;
- CAA=
- cerebral amyloid angiopathy;
- CMB=
- cerebral microbleeds;
- CVD=
- cerebrovascular disease;
- DWMH=
- deep white matter hyperintensities;
- FHS=
- Framingham Heart Study;
- ICH=
- intracerebral hemorrhage;
- OR=
- odds ratio;
- PVH=
- periventricular white matter hyperintensities;
- Sydney-MAS=
- Sydney Memory and Ageing Study;
- WMH=
- white matter hyperintensities
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Supplemental data at www.neurology.org
- Received September 24, 2012.
- Accepted in final form April 4, 2013.
- © 2013 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Fabricio Ferreira de Oliveira and Dr. Alan Cronemberger Andrade
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Research
Prevalence of and risk factors for cerebral microbleeds in a general Japanese elderly communityTomohiro Yubi, Jun Hata, Tomoyuki Ohara et al.Neurology: Clinical Practice, May 23, 2018 -
Article
Cerebral microbleedsPrevalence and relationship to amyloid burdenJonathan Graff-Radford, Hugo Botha, Alejandro A. Rabinstein et al.Neurology, December 19, 2018 -
Article
White matter hyperintensity patterns in cerebral amyloid angiopathy and hypertensive arteriopathyAndreas Charidimou, Gregoire Boulouis, Kellen Haley et al.Neurology, January 08, 2016 -
Article
APOE ε4, white matter hyperintensities, and cognition in Alzheimer and Lewy body dementiaSaira Saeed Mirza, Usman Saeed, Jo Knight et al.Neurology, October 01, 2019